F8 and hemophilia A: In contrast to conventional treatment, extended half-life products reduce the frequency of factor replacement injections. A biphasic monoclonal antibody (Emicizumab; Roche, Portugal) mimicking activated FVIII, has also been approved for patients with hemophilia A with/without inhibitors.